This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Crinetics (CRNX) Up as Second Acromegaly Study Meets Goals
by Zacks Equity Research
Crinetics (CRNX) stock rises after achieving goals in the second late-stage study evaluating paltusotine in patients with acromegaly who are treatment-naive or not currently receiving medical therapy.
GSK Outperforms Industry on Strength in Key Drugs & Vaccines
by Zacks Equity Research
Strong sales growth of GSK's specialty drugs and vaccines, the contribution from new products and positive pipeline updates should drive the stock in the future quarters.
Recent Price Trend in ADMA Biologics (ADMA) is Your Friend, Here's Why
by Zacks Equity Research
ADMA Biologics (ADMA) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.
Hoth Therapeutics (HOTH) Up on Upbeat Alzheimer's Drug Data
by Zacks Equity Research
Hoth Therapeutics (HOTH) rises on encouraging pre-clinical data demonstrating cognitive benefits of its novel therapeutic candidate, HT-ALZ, in the treatment of Alzheimer's disease.
AstraZeneca (AZN) Follows Boehringer, to Cap Inhaler Cost in US
by Zacks Equity Research
AstraZeneca (AZN) plans to lower the prices of its inhaled respiratory products to $35 per month in the United States. However, the company intends to start this in June 2024.
Intellia (NTLA) Begins Dosing in Phase III ATTR Amyloidosis Study
by Zacks Equity Research
Intellia (NTLA) doses the first patient in the phase III MAGNITUDE study on NTLA-2001 for treating transthyretin amyloidosis with cardiomyopathy.
Fennec (FENC) Signs Licensing Deal With Norgine, Stock Up
by Zacks Equity Research
Fennec (FENC) signs a licensing deal with Nordine, granting the latter rights to Pedmarqsi in the EU, Australia and New Zealand to treat cisplatin-induced hearing loss. The stock rises 11.4%.
Journey Medical (DERM) Up as FDA Accepts Skin Disease Drug NDA
by Zacks Equity Research
Journey Medical (DERM) stock rises as the FDA accepts its regulatory filing for review seeking approval for DFD-29 to treat inflammatory lesions and erythema of rosacea in adults.
Aquestive (AQST) Up as Anaphylm Pivotal Study Meets Goals
by Zacks Equity Research
Aquestive's (AQST) stock rises after meeting primary and secondary goals in the pivotal study of Anaphylm Sublingual Film to treat severe allergic reactions, including anaphylaxis.
Cybin (CYBN) Begins Phase II Study on Anxiety Drug, Stock Up
by Kanishka Das
Cybin (CYBN) initiates a phase II proof-of-concept study evaluating CYB004 for the treatment of generalized anxiety disorder. The stock rises 7.2%.
Immuneering (IMRX) Plummets 71% in One Week: Here's Why
by Zacks Equity Research
Immuneering (IMRX) plunges after multiple Wall Street analysts downgraded the stock on lackluster results from an early-stage study evaluating its lead drug across advanced RAS-mutant solid tumors.
Wall Street Analysts Think Adma Biologics (ADMA) Could Surge 33.56%: Read This Before Placing a Bet
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 33.6% in Adma Biologics (ADMA). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Bristol Myers' (BMY) Abecma Gets ODAC Votes for Label Expansion
by Zacks Equity Research
Bristol Myers' (BMY) Abecma gets eight out of 11 votes from the FDA's ODAC for patients with triple-class exposed relapsed or refractory multiple myeloma in earlier lines of therapy.
Wall Street Analysts See Adma Biologics (ADMA) as a Buy: Should You Invest?
by Zacks Equity Research
The average brokerage recommendation (ABR) for Adma Biologics (ADMA) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?
J&J (JNJ) Gets FDA Panel Vote for Carvykti's Expanded Use
by Zacks Equity Research
J&J (JNJ) is looking for expansion of Carvykti's label for the treatment of adult patients with relapsed and lenalidomide-refractory multiple myeloma.
Adma Biologics (ADMA) Stock Moves -0.5%: What You Should Know
by Zacks Equity Research
Adma Biologics (ADMA) closed at $5.99 in the latest trading session, marking a -0.5% move from the prior day.
Are Medical Stocks Lagging Adicet Bio (ACET) This Year?
by Zacks Equity Research
Here is how Adicet Bio, Inc. (ACET) and Adma Biologics (ADMA) have performed compared to their sector so far this year.
Mirum's (MIRM) Livmarli Receives FDA Nod for Expanded Use
by Zacks Equity Research
Mirum's (MIRM) Livmarli gets FDA approval for label expansion to include the treatment of cholestatic pruritus in patients aged five years and older with PFIC.
Allogene's (ALLO) Q4 Loss Narrower Than Expected, Sales Miss
by Zacks Equity Research
Allogene's (ALLO) fourth-quarter earnings beat estimates, but sales miss the mark. Management expects operating expenses for 2024 to be around $280 million.
Bristol Myers (BMY) Gets FDA Nod for Breyanzi's Label Expansion
by Zacks Equity Research
Bristol Myers (BMY) obtains FDA approval for the label expansion of CAR T cell therapy, Breyanzi, for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
Geron (GERN) Gets ODAC Votes for Blood Disorder Drug, Shares Up
by Zacks Equity Research
Geron's (GERN) pipeline candidate, imetelstat, gets FDA Committee backing for the treatment of transfusion-dependent (TD) anemia in adult patients with low-to-intermediate-1 risk myelodysplastic syndromes.
AstraZeneca (AZN) to Acquire Amolyt Pharma for $1.05 Billion
by Zacks Equity Research
AstraZeneca (AZN) enters into an agreement to acquire Amolyt Pharma to strengthen its rare disease pipeline by adding the latter's late-stage hypoparathyroidism treatment candidate, eneboparatide.
Pfizer (PFE) Gets EU Nod for Expanded Use of Pneumococcal Jab
by Zacks Equity Research
Following the label expansion, Pfizer's (PFE) 20-valent pneumococcal conjugate vaccine is authorized for use in individuals aged six weeks and older.
Pacira's (PCRX) Knee Osteoarthritis Drug Gets FDA's RMAT Tag
by Zacks Equity Research
Pacira (PCRX) receives the FDA's RMAT designation for its gene-therapy product candidate, PCRX-201, which is currently being developed in an early-stage study to treat osteoarthritis of the knee.
NewAmsterdam (NAMS) Doses Patient in HeFH Study, Shares Up
by Zacks Equity Research
NewAmsterdam (NAMS) gains on the initiation of a phase III study evaluating fixed-dose combination of obicetrapib and ezetimibe in patients with HeFH and/or ASCVD.